C

C. a steady development of lumbar and renal lymph node metastases during tumor development. Besides predominantly occurring lymphatic metastases, we visualized the formation of hematogenous metastases utilizing red fluorescent protein (RFP) expressing C33A-RFP cells. RFP positive cancer cells were found migrating in blood vessels and forming micrometastases in lungs of tumor-bearing mice. Next, we set out to analyze the influence of oncolytic virotherapy in the C33A-RFP model and exhibited an efficient virus-mediated reduction of tumor size and metastatic burden. These results suggest the C33A-RFP cervical cancer model as Metergoline a new platform to analyze cancer metastases as well as to test novel treatment options to combat metastases. Introduction Metastatic spread of tumors is usually a multistage process during which malignant cells disseminate from the primary tumor to distant organs [1]. Tumor cells migrate via two major routes: The lymphatic system and the blood circulation. During lymphatic metastasis, a common feature for most carcinomas, tumor Mouse monoclonal to OCT4 cells leave the original tumor site and migrate after settlement in regional lymph nodes to distant ones [2]. Diagnosis of lymph node metastases is usually of major importance. Even though, lymph node metastases themselves are rarely life threatening they indicate the state of tumor progression [3]. Most cancer deaths are due to development of metastases. Therefore, a broader understanding of the biology of metastases is necessary. Three major platforms are currently used to develop metastasis models. These include chemical induction, whereby carcinogens are administered to induce tumorigenesis and metastasis, syngeneic and xenograft transplant models that involve the transplantation of tumor cells/tissue into murine hosts and genetically designed mouse models [4]C[5]. Here, we are working with a xenogeneic spontaneous transplant model of metastasis. A number of xenogeneic metastasis models have been generated during the last years, for example, for prostate [6]C[8], colorectal [9]C[10], breast [11]C[12], gastric [13]C[14] or renal cell [15] carcinomas. Additionally, there are also some models of human papillomavirus (HPV) positive cervical cancer described [16]C[18]. In the course of a cervical cancer screening study (HPV positive and HPV unfavorable cell lines) for oncolytic virotherapy the effects of the oncolytic vaccinia computer virus GLV-1h68 on these cell lines was analyzed. The results indicate that this presences and the copy number of HPV DNA in cervical cancer cells did not have an impact on the therapeutic efficacy of GLV-1h68 (Table S1). Furthermore Metergoline we discovered the formation of lymph node metastases after subcutaneous implantation of C33A HPV-negative human cervical cancer cells in immunocompromised mice. Therefore, in this study, we focused on the characterization of the metastasizing ability of this cell line, which has not been described in the literature so far. We analyzed the lymphatic and the hematogenous spread of C33A-RFP cells in nude mice after subcutaneous implantation of tumor cells, whereby lymphatic circulation represented the main route of metastasizing tumor cells. Moreover, a steady progression of lymph node metastases in correlation with the tumor growth was demonstrated. In addition, we analyzed oncolytic virotherapy of C33A tumors and metastases as a novel treatment option. Oncolytic viruses are able to selectively replicate in cancer cells, resulting in destruction of tumor tissue, but leaving healthy tissues unharmed [19]. Here, we focused on studying the effect of the previously described attenuated, recombinant vaccinia computer virus GLV-1h68 [20]C[21]. The therapeutic effect of this computer virus on primary tumors has been shown for many carcinomas such as breast, pancreatic or prostate cancer [21]C[23]. Furthermore, we recently showed a therapeutic potential of GLV-1h68 in treating lymphatic and hematogenous metastases originating from the human prostate carcinoma cell line PC-3 [22], indicating that GLV-1h68 might be able to eradicate metastases in the C33A-model as well. Indeed, here we exhibited a drastic virus-mediated reduction of C33A-RFP tumors and their metastatic burden. Materials and Methods Cell lines The HPV-negative human cervical cancer cell line C33A was cultured in DMEM High Glucose (PAA Laboratories, C?lbe, Germany) supplemented with 10% FCS (PAA Laboratories, C?lbe, Germany) and 1% gentamicin answer (PAA Laboratories, C?lbe, Germany). The C33A cell line was kindly provided by Frank Stubenrauch, PhD (UKT, University of Tbingen; [24]). Authenticity of C33A cells was verified by the DSMZ GmbH Metergoline (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). C33A-RFP cells were cultured under same conditions except for adding 5 g/mL blasticidin. Human epithelial kidney cells (293FT) were obtained from Invitrogen GmbH (Karlsruhe, Germany) and cultured in RPMI 1640 supplemented with 10% FCS and.